{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T10:07:16Z","timestamp":1779530836351,"version":"3.53.1"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:p>Isatuximab, approved for the treatment of relapsed\/refractory multiple myeloma in 2020, lacks sufficient long-term safety profile in real-world clinical practice. Leveraging the FDA adverse event reporting system over a 5-year period, this study conducted a comprehensive pharmacovigilance study integrating 4 disproportionality analyses to identify isatuximab-related adverse events. Data extraction and standardization from FAERS were conducted using R and MedDRA. Concurrently, transcriptomic profiling via single-sample Gene Set Enrichment Analysis (ssGSEA) of 50 hallmark gene sets elucidated potential immunological mechanisms. Among 1884 AE reports attributing isatuximab as the primary suspect, significant signals emerged across 25 system organ classes and 129 preferred terms, with high disproportionality for neutropenia, pneumonia, and kidney injury. Tumor lysis syndrome and hypoproteinemia were newly detected and unlisted on the drug label, while females demonstrated elevated urinary tract infection risk. Transcriptomically, the CD38-high group exhibited marked upregulation of immune activation such as interferon gamma response and metabolic stress pathways including fatty acid metabolism and apoptosis, suggesting a dual phenotype of immunosuppression and hyperinflammation that may predispose to infections and renal toxicity. By synergizing real-world pharmacovigilance with transcriptomic data, this study delineates novel clinical AE signals and mechanistic insights linking CD38-driven immunometabolic dysregulation to isatuximab toxicity. These findings underscore the imperative for vigilant monitoring and tailored therapeutic strategies to mitigate risks of immune dysfunction, informing both clinical practice and future biomarker-driven interventions.<\/jats:p>","DOI":"10.1097\/md.0000000000045941","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T22:01:52Z","timestamp":1764972112000},"page":"e45941","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The real-world safety profile and potential mechanism of isatuximab: Integration of pharmacovigilance and transcriptomic analysis"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3385-8298","authenticated-orcid":false,"given":"Xiufang","family":"Weng","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Affiliated Fuzhou First Hospital of Fujian Medical University, Fuzhou, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfei","family":"Ren","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Dali University, Dali, Yunnan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7743-6917","authenticated-orcid":false,"given":"Qingqing","family":"Hao","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Fudan University, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260523","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1053\/j.seminoncol.2022.01.005","article-title":"Pathogenic signaling in multiple myeloma.","volume":"49","author":"Bolomsky","year":"2022","journal-title":"Semin Oncol"},{"key":"R2-20260523","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"R3-20260523","doi-asserted-by":"crossref","first-page":"1050522","DOI":"10.3389\/fimmu.2022.1050522","article-title":"Chimeric antigen receptor T-cell therapy for multiple myeloma.","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"R4-20260523","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.hoc.2023.04.004","article-title":"Proteasome inhibitor-based regimens in the frontline management of waldenstr\u00f6m macroglobulinemia.","volume":"37","author":"Solia","year":"2023","journal-title":"Hematol Oncol Clin North Am"},{"key":"R5-20260523","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.clml.2018.08.016","article-title":"Role of proteasome inhibitors in relapsed and\/or refractory multiple myeloma.","volume":"19","author":"Leleu","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R6-20260523","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/jbmr.4496","article-title":"Bone-targeted bortezomib inhibits bortezomib-resistant multiple myeloma in mice by providing higher levels of bortezomib in bone.","volume":"37","author":"Tao","year":"2022","journal-title":"J Bone Miner Res"},{"key":"R7-20260523","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/bjh.16881","article-title":"Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma.","volume":"191","author":"Kuwahara-Ota","year":"2020","journal-title":"Br J Haematol"},{"key":"R8-20260523","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.bbrc.2021.08.051","article-title":"Involvement of EZH2 inhibition in lenalidomide and pomalidomide-mediated growth suppression in HTLV-1-infected cellsEZH 2.","volume":"574","author":"Kondo","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"R9-20260523","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3390\/biom13050747","article-title":"A new generation of IMIDs as treatments for neuroinflammatory and neurodegenerative disorders.","volume":"13","author":"Kopp","year":"2023","journal-title":"Biomolecules"},{"key":"R10-20260523","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1358\/dot.2021.57.10.3313853","article-title":"Daratumumab for the treatment of multiple myeloma.","volume":"57","author":"Goldsmith","year":"2021","journal-title":"Drugs Today (Barc)"},{"key":"R11-20260523","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s11523-021-00827-0","article-title":"Isatuximab: a review of its use in multiple myeloma.","volume":"16","author":"Frampton","year":"2021","journal-title":"Target Oncol"},{"key":"R12-20260523","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12916-022-02305-4","article-title":"Selinexor plus low-dose dexamethasone in Chinese patients with relapsed\/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.","volume":"20","author":"Qiu","year":"2022","journal-title":"BMC Med"},{"key":"R13-20260523","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/17474086.2021.1924052","article-title":"An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma.","volume":"14","author":"Piggin","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"R14-20260523","doi-asserted-by":"crossref","first-page":"108722","DOI":"10.1016\/j.intimp.2022.108722","article-title":"Drug resistance biomarker ABCC4 of selinexor and immune feature in multiple myeloma.","volume":"108","author":"Hu","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"R15-20260523","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/jha2.709","article-title":"Selinexor: targeting a novel pathway in multiple myeloma.","volume":"4","author":"Mo","year":"2023","journal-title":"EJHaem"},{"key":"R16-20260523","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40259-021-00514-6","article-title":"Targeting nuclear export proteins in multiple myeloma therapy.","volume":"36","author":"Richard","year":"2022","journal-title":"BioDrugs"},{"key":"R17-20260523","doi-asserted-by":"crossref","first-page":"106576","DOI":"10.1016\/j.leukres.2021.106576","article-title":"Isatuximab plus pomalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.","volume":"104","author":"Bringhen","year":"2021","journal-title":"Leuk Res"},{"key":"R18-20260523","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12185-024-03800-5","article-title":"Isatuximab with pomalidomide-dexamethasone in relapsed\/refractory multiple myeloma: post-marketing surveillance in Japan.","volume":"120","author":"Tagami","year":"2024","journal-title":"Int J Hematol"},{"key":"R19-20260523","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S2352-3026(24)00070-X","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial.","volume":"11","author":"O\u2019Donnell","year":"2024","journal-title":"Lancet Haematol"},{"key":"R20-20260523","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"R21-20260523","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(22)00019-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.","volume":"23","author":"Richardson","year":"2022","journal-title":"Lancet Oncol"},{"key":"R22-20260523","first-page":"2139","article-title":"Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial.","volume":"110","author":"Manier","year":"2025","journal-title":"Haematologica"},{"key":"R23-20260523","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1007\/s00277-025-06343-9","article-title":"Efficacy and safety of isatuximab monotherapy to treat relapsed or refractory multiple myeloma: a pooled analysis of clinical trials.","volume":"104","author":"Dimopoulos","year":"2025","journal-title":"Ann Hematol"},{"key":"R24-20260523","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat Med"},{"key":"R25-20260523","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.3389\/fimmu.2020.01771","article-title":"Isatuximab acts through Fc-dependent, independent, and direct pathways to kill multiple myeloma cells.","volume":"11","author":"Zhu","year":"2020","journal-title":"Front Immunol"},{"key":"R26-20260523","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-019-0198-4","article-title":"Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma.","volume":"9","author":"Martin","year":"2019","journal-title":"Blood Cancer J"},{"key":"R27-20260523","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/hon.3105","article-title":"Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed\/refractory multiple myeloma: an update of the phase 1\/2 ISLANDs study.","volume":"41","author":"Sunami","year":"2023","journal-title":"Hematol Oncol"},{"key":"R28-20260523","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/13543784.2025.2532446","article-title":"Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions.","volume":"34","author":"Richardson","year":"2025","journal-title":"Expert Opin Investig Drugs"},{"key":"R29-20260523","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/frhem.2024.1335161","article-title":"First clinical experience of isatuximab safety and tolerability in relapsed and refractory multiple myeloma: real-world data from a compassionate use program in Germany.","volume":"3","author":"Leitner","year":"2024","journal-title":"Front Hematol"},{"key":"R30-20260523","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood-2019-02-895193","article-title":"A phase 1b study of isatuximab plus pomalidomide\/dexamethasone in relapsed\/refractory multiple myeloma.","volume":"134","author":"Mikhael","year":"2019","journal-title":"Blood"},{"key":"R31-20260523","doi-asserted-by":"crossref","first-page":"S947","DOI":"10.1016\/S2152-2650(25)02654-0","article-title":"MM-897: efficacy of isatuximab plus dexamethasone versus no isatuximab-based treatments in refractory multiple myeloma: a systematic review and meta-analysis.","volume":"25","author":"Castillo","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R32-20260523","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1080\/14740338.2023.2296966","article-title":"Safety of daratumumab in the real-world: a pharmacovigilance study based on FAERS database.","volume":"23","author":"Wu","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"R33-20260523","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2147\/CLEP.S365513","article-title":"A real-world disproportionality analysis of olaparib: data mining of the public version of FDA adverse event reporting system.","volume":"14","author":"Shu","year":"2022","journal-title":"Clin Epidemiol"},{"key":"R34-20260523","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1159\/000540542","article-title":"Real-world disproportionality analysis of the food and drug administration adverse event reporting system database for asciminib.","volume":"102","author":"Liu","year":"2024","journal-title":"Oncology (Huntingt)"},{"key":"R35-20260523","doi-asserted-by":"crossref","first-page":"e27529","DOI":"10.1016\/j.heliyon.2024.e27529","article-title":"A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib.","volume":"10","author":"Lin","year":"2024","journal-title":"Heliyon"},{"key":"R36-20260523","doi-asserted-by":"crossref","first-page":"12231","DOI":"10.1038\/s41598-024-62852-z","article-title":"Adverse events reporting of XPO1 inhibitor-selinexor: a real-word analysis from FAERS database.","volume":"14","author":"Liu","year":"2024","journal-title":"Sci Rep"},{"key":"R37-20260523","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40360-023-00702-w","article-title":"A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).","volume":"24","author":"Zou","year":"2023","journal-title":"BMC Pharmacol Toxicol"},{"key":"R38-20260523","doi-asserted-by":"crossref","first-page":"944342","DOI":"10.3389\/fphar.2022.944342","article-title":"Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1\/PD-L1 inhibitors.","volume":"13","author":"Chen","year":"2022","journal-title":"Front Pharmacol"},{"key":"R39-20260523","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.3346\/jkms.2018.33.e213","article-title":"Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records.","volume":"33","author":"Kim","year":"2018","journal-title":"J Korean Med Sci"},{"key":"R40-20260523","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1038\/s41598-024-83630-x","article-title":"A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast.","volume":"15","author":"Hou","year":"2025","journal-title":"Sci Rep"},{"key":"R41-20260523","doi-asserted-by":"crossref","first-page":"20705","DOI":"10.1038\/s41598-023-47906-y","article-title":"A population-based study on incidence trends of myeloma in the United States over 2000-2020.","volume":"13","author":"Mousavi","year":"2023","journal-title":"Sci Rep"},{"key":"R42-20260523","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41385-022-00549-0","article-title":"The impact of biological sex on diseases of the urinary tract.","volume":"15","author":"Deltourbe","year":"2022","journal-title":"Mucosal Immunol"},{"key":"R43-20260523","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.3390\/ph16111542","article-title":"Insight into risk factors, pharmacogenetics\/genomics, and management of adverse drug reactions in elderly: a narrative review.","volume":"16","author":"Bellanca","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"R44-20260523","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41408-023-00923-6","article-title":"Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.","volume":"13","author":"Martin","year":"2023","journal-title":"Blood Cancer J"},{"key":"R45-20260523","doi-asserted-by":"crossref","first-page":"31859","DOI":"10.1038\/s41598-024-83014-1","article-title":"Comprehensive safety evaluation of isatuximab in multiple myeloma using disproportionality analysis of FAERS and meta-analysis of randomized controlled trials.","volume":"14","author":"Favas Karimbanathottathil","year":"2024","journal-title":"Sci Rep"},{"key":"R46-20260523","doi-asserted-by":"crossref","first-page":"e006262","DOI":"10.1136\/jitc-2022-006262","article-title":"Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor).","volume":"11","author":"Siddiqui","year":"2023","journal-title":"J ImmunoTher Cancer"},{"key":"R47-20260523","doi-asserted-by":"crossref","first-page":"1346178","DOI":"10.3389\/fimmu.2024.1346178","article-title":"Counterproductive effects of anti-CD38 and checkpoint inhibitor for the treatment of NK\/T cell lymphoma.","volume":"15","author":"Lee","year":"2024","journal-title":"Front Immunol"},{"key":"R48-20260523","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1007\/s00262-020-02687-5","article-title":"Increased Th17 activation and gut microbiota diversity are associated with pembrolizumab-triggered tuberculosis.","volume":"69","author":"Zhang","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"R49-20260523","doi-asserted-by":"crossref","first-page":"S340","DOI":"10.1016\/S2152-2650(24)01254-0","article-title":"CLL-033 an unusual case of renal infiltration in chronic lymphocytic leukemia.","volume":"24","author":"Peshin","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R50-20260523","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2024-207440","article-title":"Single-cell spatial proteomic characterization of clonal plasma cell and immune cell metabolism within the bone marrow microenvironment in high-risk smoldering multiple myeloma and its association with progression to multiple myeloma.","volume":"144","author":"Soekojo","year":"2024","journal-title":"Blood"},{"key":"R51-20260523","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1182\/blood-2024-205481","article-title":"Depletion of mature b cells and of normal plasma cells (PC) behind the higher incidence of infections after Anti-BCMA VS Anti-GPRC5D bispecific antibodies (bsAb) in relapsed refractory multiple myeloma (RRMM).","volume":"144","author":"Jelinek","year":"2024","journal-title":"Blood"},{"key":"R52-20260523","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1182\/blood-2024-210232","article-title":"De novo resistance and relapse from daratumumab monotherapy in ndmm is associated with immune evasion and immunosuppression.","volume":"144","author":"Meads","year":"2024","journal-title":"Blood"},{"key":"R53-20260523","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood-2024-211269","article-title":"Disrupting mitochondrial dynamics and metabolism in leukemic stem cells through mitochondrial pcna inhibition: the role of aoh1996.","volume":"144","author":"Kang","year":"2024","journal-title":"Blood"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045941","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T10:01:57Z","timestamp":1779530517000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":53,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045941","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"2025-07-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}